Akynzeo to help Eisai Over Aloxi exclusivity loss?
This article was originally published in Scrip
Executive Summary
The new US regulatory clearance for Eisai and Helsinn Group's Akynzeo is the first to be granted to a single-capsule anti-emetic product targeting two distinct treatment pathways, and will be an important addition to Eisai's oncology franchise.